Herpes Zoster Vaccine (Zostavax)
A live attenuated varicella-zoster vaccine (Zostavax - Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons ≥60 years old. Each dose of Zostavax contains about 14 times as much varicella-zoster virus (VZV) as Varivax, which has been used in the US since 1995 to vaccinate against varicella (chicken pox)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Herpes Zoster Vaccine (Zostavax)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1243
Article Code: 1243a
Date: September 11, 2006
Volume: 48
Pages: 73-74
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1243
Article Code: 1243a
Date: September 11, 2006
Volume: 48
Pages: 73-74
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)